Arrowhead Pharmaceuticals (ARWR) Reaches Five-Year High as Plozasiran Nears sNDA Submission
Arrowhead Pharmaceuticals' stock surged to a five-year high following strong Phase 3 trial results for plozasiran, which showed significant reductions in triglyceride levels and acute pancreatitis cases. The company plans to submit an sNDA by year-end for expanded use of the drug.
Topics: Arrowhead Pharmaceuticals FDA sNDA submission hypertriglyceridemia treatment plozasiran